company background image
GRAN

Granules IndiaNSEI:GRANULES Stock Report

Last Price

₹317.30

Market Cap

₹78.7b

7D

-5.2%

1Y

-9.0%

Updated

19 Jan, 2022

Data

Company Financials +
GRANULES fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends5/6

GRANULES Stock Overview

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally.

Granules India Competitors

Laurus Labs

BSE:540222

₹267.3b

Glenmark Life Sciences

BSE:543322

₹73.5b

Shilpa Medicare

BSE:530549

₹47.6b

Aarti Drugs

BSE:524348

₹47.4b

Price History & Performance

Summary of all time highs, changes and price drops for Granules India
Historical stock prices
Current Share Price₹317.30
52 Week High₹404.80
52 Week Low₹280.50
Beta0.47
1 Month Change3.09%
3 Month Change-2.44%
1 Year Change-9.01%
3 Year Change240.09%
5 Year Change175.08%
Change since IPO2,946.57%

Recent News & Updates

Dec 21
These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Aug 18
Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock

Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

GRANULESIN PharmaceuticalsIN Market
7D-5.2%-1.3%-1.1%
1Y-9.0%9.3%32.6%

Return vs Industry: GRANULES underperformed the Indian Pharmaceuticals industry which returned 9.5% over the past year.

Return vs Market: GRANULES underperformed the Indian Market which returned 34.4% over the past year.

Price Volatility

Is GRANULES's price volatile compared to industry and market?
GRANULES volatility
GRANULES Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.7%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.1%

Stable Share Price: GRANULES is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: GRANULES's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19843,369Krishna Chigurupatihttps://www.granulesindia.com

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology.

Granules India Fundamentals Summary

How do Granules India's earnings and revenue compare to its market cap?
GRANULES fundamental statistics
Market Cap₹78.67b
Earnings (TTM)₹4.75b
Revenue (TTM)₹33.82b

16.6x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRANULES income statement (TTM)
Revenue₹33.82b
Cost of Revenue₹16.28b
Gross Profit₹17.54b
Expenses₹12.79b
Earnings₹4.75b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)19.16
Gross Margin51.87%
Net Profit Margin14.05%
Debt/Equity Ratio40.8%

How did GRANULES perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

8%

Payout Ratio

Valuation

Is Granules India undervalued compared to its fair value and its price relative to the market?

16.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GRANULES (₹317.3) is trading below our estimate of fair value (₹380.67)

Significantly Below Fair Value: GRANULES is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: GRANULES is good value based on its PE Ratio (16.6x) compared to the Indian Pharmaceuticals industry average (25.9x).

PE vs Market: GRANULES is good value based on its PE Ratio (16.6x) compared to the Indian market (23.4x).


Price to Earnings Growth Ratio

PEG Ratio: GRANULES is good value based on its PEG Ratio (0.7x)


Price to Book Ratio

PB vs Industry: GRANULES's PB Ratio (3.3x) is in line with the IN Pharmaceuticals industry average.


Future Growth

How is Granules India forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

23.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GRANULES's forecast earnings growth (23.7% per year) is above the savings rate (6.7%).

Earnings vs Market: GRANULES's earnings (23.7% per year) are forecast to grow faster than the Indian market (20.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GRANULES's revenue (17.2% per year) is forecast to grow faster than the Indian market (13.2% per year).

High Growth Revenue: GRANULES's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GRANULES's Return on Equity is forecast to be high in 3 years time (20.8%)


Past Performance

How has Granules India performed over the past 5 years?

31.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GRANULES has high quality earnings.

Growing Profit Margin: GRANULES's current net profit margins (14.1%) are lower than last year (14.9%).


Past Earnings Growth Analysis

Earnings Trend: GRANULES's earnings have grown significantly by 31.2% per year over the past 5 years.

Accelerating Growth: GRANULES's earnings growth over the past year (10.2%) is below its 5-year average (31.2% per year).

Earnings vs Industry: GRANULES earnings growth over the past year (10.2%) underperformed the Pharmaceuticals industry 29.7%.


Return on Equity

High ROE: GRANULES's Return on Equity (20.1%) is considered high.


Financial Health

How is Granules India's financial position?


Financial Position Analysis

Short Term Liabilities: GRANULES's short term assets (₹22.1B) exceed its short term liabilities (₹14.1B).

Long Term Liabilities: GRANULES's short term assets (₹22.1B) exceed its long term liabilities (₹3.5B).


Debt to Equity History and Analysis

Debt Level: GRANULES's net debt to equity ratio (25.7%) is considered satisfactory.

Reducing Debt: GRANULES's debt to equity ratio has reduced from 76% to 40.8% over the past 5 years.

Debt Coverage: GRANULES's debt is well covered by operating cash flow (48.9%).

Interest Coverage: GRANULES's interest payments on its debt are well covered by EBIT (84.9x coverage).


Balance Sheet


Dividend

What is Granules India current dividend yield, its reliability and sustainability?

0.47%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GRANULES's dividend (0.47%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).

High Dividend: GRANULES's dividend (0.47%) is low compared to the top 25% of dividend payers in the Indian market (1.33%).


Stability and Growth of Payments

Stable Dividend: GRANULES's dividends per share have been stable in the past 10 years.

Growing Dividend: GRANULES's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (7.8%), GRANULES's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GRANULES's dividends in 3 years are forecast to be thoroughly covered by earnings (4.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Krishna Chigurupati (67 yo)

no data

Tenure

₹419,449,000

Compensation

Dr. Krishna Prasad Chigurupati, B.Sc. had been Managing Director of Granules India Limited since September 1, 2009. He serves as Chairman of Granules India Limited and has been its Non-Independent Executiv...


CEO Compensation Analysis

Compensation vs Market: Krishna's total compensation ($USD5.62M) is above average for companies of similar size in the Indian market ($USD352.52K).

Compensation vs Earnings: Krishna's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: GRANULES's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: GRANULES's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Granules India Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Granules India Limited
  • Ticker: GRANULES
  • Exchange: NSEI
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹78.667b
  • Shares outstanding: 248.01m
  • Website: https://www.granulesindia.com

Number of Employees


Location

  • Granules India Limited
  • My Home Hub
  • 2nd Floor
  • Hyderabad
  • 500081
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 15:46
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.